Developing nutritional component chrysin as a therapeutic agent: Bioavailability and pharmacokinetics consideration, and ADME mechanisms
Gao S, Siddiqui N, Etim I, Du T, Zhang Y
Published in Biomedicine & Pharmacotherapy
Methodology
Review of preclinical and clinical pharmacokinetic studies analysing chrysin absorption, metabolism and efflux
Key Findings
Low aqueous solubility, rapid UGT/SULT metabolism and BCRP/MRP2 efflux give chrysin very poor systemic bioavailability, while gut-lumen exposure stays high.
Conclusions
Clinical results with oral chrysin have been largely negative; systemic effects seen in vitro are unlikely to translate.
Limitations
Narrative synthesis; few human pharmacokinetic datasets available.
Supplements Studied
Although chrysin's biological activities have been demonstrated and the mechanism of actions has been determined using in vitro and in vivo models, results from the current clinical studies were largely negative.
Outcomes Measured
A potential reason for chrysin's low efficacy in humans is poor oral bioavailability.
Study Details
Access Study
Disclosures
Funding
Not reported
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.